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Abstract
Background: Serological (antibody detection) tests for tuberculosis (TB) are widely used in developing countries. As part of
a World Health Organization policy process, we performed an updated systematic review to assess the diagnostic accuracy
of commercial serological tests for pulmonary and extrapulmonary TB with a focus on the relevance of these tests in low-
and middle-income countries.
Methods and Findings: We used methods recommended by the Cochrane Collaboration and GRADE approach for rating
quality of evidence. In a previous review, we searched multiple databases for papers published from 1 January 1990 to 30
May 2006, and in this update, we add additional papers published from that period until 29 June 2010. We prespecified
subgroups to address heterogeneity and summarized test performance using bivariate random effects meta-analysis. For
pulmonary TB, we included 67 studies (48% from low- and middle-income countries) with 5,147 participants. For all tests,
estimates were variable for sensitivity (0% to 100%) and specificity (31% to 100%). For anda-TB IgG, the only test with
enough studies for meta-analysis, pooled sensitivity was 76% (95% CI 63%–87%) in smear-positive (seven studies) and 59%
(95% CI 10%–96%) in smear-negative (four studies) patients; pooled specificities were 92% (95% CI 74%–98%) and 91%
(95% CI 79%–96%), respectively. Compared with ELISA (pooled sensitivity 60% [95% CI 6%–65%]; pooled specificity 98%
[95% CI 96%–99%]), immunochromatographic tests yielded lower pooled sensitivity (53%, 95% CI 42%–64%) and
comparable pooled specificity (98%, 95% CI 94%–99%). For extrapulmonary TB, we included 25 studies (40% from low- and
middle-income countries) with 1,809 participants. For all tests, estimates were variable for sensitivity (0% to 100%) and
specificity (59% to 100%). Overall, quality of evidence was graded very low for studies of pulmonary and extrapulmonary TB.
Conclusions: Despite expansion of the literature since 2006, commercial serological tests continue to produce inconsistent
and imprecise estimates of sensitivity and specificity. Quality of evidence remains very low. These data informed a recently
published World Health Organization policy statement against serological tests.
Please see later in the article for the Editors’ Summary.
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Despite impressive advances in tuberculosis (TB) control over the
last decade [1], missed diagnoses continue to fuel the global
epidemic, leading to more severe illness for patients and enabling
further transmission of Mycobacterium tuberculosis [2]. Smear micros-
copy and chest radiography, the primary tools used in resource-
limitedcountriesforidentifying TB,oftenperformpoorly,especially
in HIV-coinfected patients [3–5]. Improved techniques, such as
liquid culture for M. tuberculosis and nucleic acid amplification tests,
are often too expensive and complex for routine use in resource-
limited settings. The Xpert MTB/RIF (Cepheid), a new technology
recently endorsed by the World Health Organization (WHO),
provides high sensitivity for detection of TB and drug resistance [6].
WHO has issued a blueprint for Xpert’s implementation [7];
however, high cost may be a barrier for scaling up this technology in
many areas where the epidemic is most severe [2].
Serological tests have a long history and have been used
successfully for the rapid diagnosis of many infectious diseases
(e.g., HIV, syphilis, and viral hepatitis). In this paper, ‘‘serological
tests’’ refers to blood tests that detect the humoral immune
(antibody) responses to M. tuberculosis antigens. Serological tests are
not to be confused with interferon-gamma release assays that
measure the T-cell-based interferon-gamma response to M.
tuberculosis antigens. In comparison with microscopy, serological
tests appear to offer several advantages: (1) the result from a
serological test using the enzyme-linked immunosorbent assay
(ELISA) format could be available within hours, and the result
using an immunochromatographic assay format, within minutes;
(2) a serological test, if developed into a point-of-care test, could
potentially replace microscopy or extend testing to lower levels of
health services; and (3) in children, for whom sputum is difficult to
obtain, and in patients suspected of having extrapulmonary TB, a
blood test may be more practical.
Although currently the International Standards for TB Care
discourages the use of serological tests in routine practice [8] and
no international guideline recommends their use, dozens of
commercial serological tests for TB diagnosis are offered for sale
in many parts of the world [9], including Afghanistan, Bangladesh,
Brazil, Cambodia, China, India, Indonesia, Kenya, Myanmar,
Nigeria, Pakistan, Philippines, Russia, South Africa, Thailand,
Uganda, and Viet Nam, as was recently found in a survey of 22
high TB burden countries [10]. For example, in India, numerous
products with claims of high accuracy in their package inserts are
available for purchase (Table S1), and an estimated 1.5 million
serological tests are performed every year [10].
We are aware of four systematic reviews and one laboratory-
based evaluation on this topic. The first review included only studies
with a cohort or case series design and searched the literature
through 2003 [11]. Performance of the tests was modest, and
sensitivity decreased when only studies meeting at least two design-
related criteria were included (seven studies, pooled sensitivity of
34%) [11]. Two subsequent reviews evaluating commercial
serological tests for pulmonary TB (68 studies) [12] and extrapul-
monary TB (21 studies) [13] found the sensitivity and specificity of
these tests to be highly variable. The fourth review, a meta-analysis
of in-house serological tests for the diagnosis of pulmonary TB (254
studies including 51 distinct single antigens and 30 distinct multiple-
antigen combinations), identified potential candidate antigens for
inclusion in an antibody-detection-based TB test in patients with
and without HIV infection; however, no single antigen achieved
sufficientsensitivity to replace smear microscopy [14]. A laboratory-
based evaluation of 19 rapid commercial tests conducted by the
WHO Special Programme for Research and Training in Tropical
Diseases found that, in comparison with culture plus clinical follow-
up, serological tests provided low and variable sensitivity (1% to
60%) and specificity (53% to 99%) [15].
Since the publication of the previous reviews, the evidence base
has grown and approaches to meta-analysis of diagnostic tests have
evolved. This updated systematic review was commissioned by
WHO to guide policy recommendations on serological tests for
TB, with a special focus on the relevance of these assays in low-
and middle-income countries. The objective of this review is to
synthesize new evidence since 2006 in order to address the
following question: what is the diagnostic accuracy of commercial
serological tests for active TB (pulmonary and extrapulmonary
TB) in adults and children, with and without HIV infection?
Specifically, we were interested in evaluating the use of a
serological assay as a replacement test for, or an additional test
after, smear microscopy.
Methods
We followed methods for conducting and reporting systematic
reviews and meta-analyses recommended by the Cochrane
Collaboration Diagnostic Test Accuracy Working Group and
the PRISMA statement (Text S1), including the preparation of a
protocol and analysis plan (Text S2) [16–18].
Selection Criteria and Definitions
Types of studies. Diagnostic studies (with any study design)
were included that evaluated serological tests for active TB
(pulmonary and extrapulmonary TB) in patients who provided
sera before or within 14 d of starting antituberculous treatment.
Participants. The participants constituted adults and child-
ren, with and without HIV infection, with suspected or confirmed
active TB, from all clinical settings (clinic or hospital). The
protocol for the current review included studies with at least ten
TB cases. Studies could be performed in any country regardless of
TB incidence or income status.
Index test. The index test was any commercial serological
test for the diagnosis of active TB.
Comparator tests. There was either no test or smear mic-
roscopy used for comparison.
Target conditions. The target conditions were pulmonary
and extrapulmonary TB.
Reference standards. Pulmonary TB required positivity on
mycobacterial culture. (The previous review accepted positivity on
either culture or smear microscopy as the reference standard [12].)
Extrapulmonary TB required positivity on at least one of the
following tests: culture, smear, or histopathological examination.
Outcomes. The outcomes were sensitivity and specificity.
Sensitivity refers to the proportion of patients with a positive
serological test result among patients with TB confirmed by the
reference standard. Specificity refers to the proportion of
participants with a negative serological test result among
participants without TB according to the reference standard. To
estimate specificity, we selected only one non-TB group if a study
had more than one such group. The preferred non-TB
participants were those in whom active TB was initially
suspected but later ruled out (‘‘other respiratory disease’’ or
‘‘mixed disease’’ groups), and who were from the same population
as TB patients.
Extrapulmonary TB. Extrapulmonary TB was classified as
lymph node, pleural, meningeal and/or central nervous system,
bone and/or joint, genitourinary, abdominal, skin, other sites,
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different sites are combined to obtain at least ten extrapulmonary
TB cases).
Country income status. Country income status was
classified according to the World Bank List of Economies [19].
Exclusion criteria. The following studies were excluded: (1)
studies published before 1990; (2) animal studies; (3) conference
abstracts and proceedings; (4) studies on the detection of latent TB
infection; (5) studies on nontuberculous mycobacterial infection;
(6) studies that used non-immunological methods for detection of
antibodies; and (7) basic science literature that focused on
detection/cloning of new antigens or their immunological
properties (i.e., early pre-clinical studies).
Search Methods
We updated the database searches (MEDLINE [1 May 2006 to
29 June 2010], BIOSIS [1 January 2005 to 10 February 2010],
EMBASE [1 October 2005 to 10 February 2010], and Web of
Science [1 January 2005 to 10 February 2010]) that were carried
out in previous systematic reviews (MEDLINE [1 January 1990 to
30 May 2006], BIOSIS [1 January 1990 to 6 December 2005],
EMBASE [1 January 1990 to 11 October 2005], and Web of
Science [1 January 1990 to 6 December 2005]) for relevant studies
that reported data on commercial serological tests for active TB.
The original search was limited to English, and the updated search
was performed without a language restriction. The search field
tags used in database searching were MeSH terms (mh), title/
abstract words (tiab), and title (ti). The terms used included:
tuberculosis[mh] OR mycobacterium tuberculosis[mh], ‘‘sensitiv-
ity and specificity’’[mh] OR diagnostic*[tiab] OR predictive value
of tests[mh] OR immunologic tests[mh] OR immunochemis-
try[mh] OR serology[ti] OR serological[ti] OR serodiagnosis[-
tiab] OR serodiagnostic[tiab] OR immunodiagnosis[tiab] OR
immunodiagnostic[tiab] OR antibody[tiab] OR antibodies[tiab]
OR elisa[tiab] OR immunosorbent[tiab] OR (western[tiab] AND
blot*[tiab]) OR immunoassay[tiab] OR ‘‘humoral immune’’ OR
‘‘humoral immunity’’ OR ‘‘humoral antibody’’ OR ‘‘immune
based’’ OR ‘‘antibody detection’’ (Text S3).
In addition to database searches, we also searched reference lists
of eligible papers and related reviews, and contacted authors and
researchers in the field to identify additional potentially relevant
published studies. For lack of time, we did not specifically seek to
identify unpublished studies.
Study Selection
Initially, two reviewers (KRS and LLF) independently screened
the accumulated citations for relevance and then independently
reviewed full-text articles using prespecified eligibility criteria.
Disagreements about study selection were resolved by discussion.
Data Extraction
A data extraction form was created and pilot-tested with a subset
of eligible studies and then finalized. Two reviewers independently
extracted data from included studies with the standardized form on
the following characteristics: study design; age group (children ,15
y ofage); HIVstatus; case countryof residence; sputum smear status
(pulmonary TB); site of TB (extrapulmonary TB); assay type (e.g.,
ELISA, immunochromatographic test); antibody class detected
(IgG, IgM, and IgA); serological test name; antigen composition;
condition of the specimen (fresh or frozen); and sensitivity and
specificity (data were extracted as true positives, false positives, false
negatives, and true negatives). In some cases, study investigators
evaluated more than one diagnostic test with the same set of
participants. In these situations, we extracted data for each test and
considered each dataset to be an independent study. For example,
Anderson et al. [20] contributed three studies evaluating three
serological tests: (1) InBios Active TbDetect IgG ELISA (InBios
International); (2) IBL M. tuberculosis IgG ELISA (IBL-Hamburg),
and (3) anda-TB IgG (Anda Biologicals) [20]. The agreement
between reviewers on data extraction for sensitivity and specificity
was 100%. Other differences between the reviewers (these
differences mainly concerned the methodological quality assess-
ment) were resolved by discussion. When necessary, we contacted
authors of papers identified through the updated literature search
for additional information.
While extracting data, we looked for studies that considered the
added value of serological tests to determine if they contributed to
active TB diagnosis beyond that ascertained by conventional tests
such as symptoms, sputum smears, and chest radiographs. In
particular, we looked for studies comparing microscopy with
microscopy plus serology or studies that performed multivariable
analysis. Since we did not identify any studies of this type, we
considered studies in smear-negative patients to provide indirect
evidence of the use of serology as an add-on test to microscopy. In
addition, we looked for information on patient-important
outcomes. Patient-important outcomes for this review could
include an increased number of TB patients detected, decreased
time to starting treatment, increased number of patients starting
TB treatment, decreased number of false-positive TB patients
treated, and decreased number of patients lost because of a
reduced number of visits. Finally, we looked for information on the
values and preferences of patients associated with these tests.
Assessment of the Methodological Quality of Individual
Studies
Two reviewers (KRS and LLF) independently assessed study
quality using the core set of 11 items from Quality Assessment of
Diagnostic Accuracy Studies (QUADAS), a validated tool to
evaluate the presence of bias and variation in diagnostic accuracy
studies [21]. As recommended, we scored each item as ‘‘yes,’’
‘‘no,’’ or ‘‘unclear.’’ We considered representative patient spec-
trum (i.e., was the spectrum of patients representative of the
patients who will receive the test in practice?) to be persons
suspected of having active TB who were consecutively or
randomly enrolled. For pulmonary TB, a score of ‘‘yes’’ for
representative spectrum also required that patients were evaluated
in an outpatient setting. For all studies, we scored the following six
items as ‘‘yes’’: acceptable reference standard (the reference
standard was a criterion for inclusion); acceptable delay between
serological test and reference standard; partial verification
avoided; incorporation avoided; reference standard results blinded
(as culture result was considered to be entirely objective in
interpretation); and relevant clinical information. ‘‘Differential
verification avoided’’ was scored as ‘‘yes’’ if all participants
suspected of having TB were evaluated with the same reference
standard or if participants without TB were reported to be
asymptomatic and healthy. ‘‘Index test (serological test) result
blinded’’ (to reference standard result) was scored as ‘‘yes’’ if this
was explicitly stated in the paper. ‘‘Uninterpretable results
reported’’ was scored as ‘‘yes’’ if uninterpretable results were des-
cribed or there was a statement about the absence of unin-
terpretable results. ‘‘Withdrawals explained’’ was scored as ‘‘yes’’ if
a flow diagram or statement was included making it clear what
happened to all participants in the study. Conflicts of interest are
known to be a concern in diagnostic studies [22]. Therefore, we
evaluated the involvement of test manufacturers. Finally, we
grouped studies according to the type of serological test or site of
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separately for each subgroup.
GRADE Quality of Evidence
We used the GRADE (Grading of Recommendations Assess-
ment, Development and Evaluation) approach, a transparent and
systematic process for making judgments about quality of the
evidence [23]. GRADE specifies four categories for quality: high,
moderate, low, and very low. These categories are then applied to
the body of evidence for each outcome, rather than to individual
studies. In the GRADE approach, the categories reflect the extent
of confidence that an estimate of effect is correct [24]. Quality
begins with a consideration of study design (e.g., randomized
controlled trials and cross-sectional studies in patients with
diagnostic uncertainty are considered high quality) and may be
compromised by five factors: limitations (risk of bias assessed by
QUADAS, such as absence of consecutive or random selection of
participants and lack of blinding of test results), indirectness (lack
of generalizability and use of test results as surrogates for patient-
important outcomes), inconsistency (unexplained heterogeneity),
imprecision (wide confidence intervals for estimates of test
accuracy), and risk of publication bias [23].
Data Analysis
Descriptive analyses were performed using SPSS (version
14.0.1.366). For each study, the sensitivity and specificity of the
serological test along with the 95% CIs were calculated, and forest
plots were generated to display sensitivity and specificity estimates
using Review Manager 5.0 (The Nordic Cochrane Center).
Heterogeneity was assessed visually using forest plots (Review
Manager 5.0).
Selection of Subgroups for Meta-Analysis
We recognized that studies were heterogeneous in many
respects, particularly concerning the serological test used, antibody
class detected, sputum smear status (pulmonary TB), and site of
extrapulmonary TB. Therefore, in order to address heterogeneity
and combine study results, subgroups of ‘‘comparable’’ tests and
extrapulmonary sites were prespecified. When possible, studies
were stratified by smear and HIV status. For meta-analysis, at least
four studies were required to be available for inclusion in a
subgroup, in order to strengthen results and reduce the possibility
of finding a significant result by chance. This classification resulted
in seven subgroups for meta-analysis (four pulmonary and three
extrapulmonary TB subgroups). As noted above, in some cases,
study investigators evaluated more than one diagnostic test with
the same participants; therefore, some meta-analyses included the
same individuals multiple times.
To summarize test performance within each subgroup, we
carried out bivariate meta-analyses that jointly modeled sensitivity
and specificity. These models weighted studies according to the
sampling variability within studies as well as the unexplained
heterogeneity between studies using a random effects approach
[25]. Subgroups were considered homogeneous with respect to a
number of observed variables. However, within a subgroup, it is
likely that the heterogeneity between studies could be explained by
measurable but unobserved quantities, e.g., the positivity cutoff,
that we could not address. Therefore, for the pooled results of
studies in the meta-analysis, we did not attempt to quantify
unobserved heterogeneity using statistics such as I
2 or chi-squared
[18]. The model was estimated using a Bayesian approach with
nonsubjective prior distributions and implemented using Win-
BUGS (version 1.4.1) [26]. We used Wilson’s method for
estimating the credible interval as this method performs well even
when the probability or the sample size is small [27]. Finally, a
hierarchical summary receiver operating characteristic (HSROC)
curve was plotted for selected meta-analyses. The HSROC curve
plots sensitivity versus specificity and provides information on the
overall performance of a test across different thresholds. The closer
the curve is to the upper left-hand corner of the plot (sensitivity
and specificity are both 100%), the better the performance of the
test [28]. The plots were made using R (version 2.6.1) [29].
Results
Pulmonary TB
Results of the search. Initially, 4,256 citations were
identified (Figure 1). After screening titles and abstracts, 160
potentially relevant full-text papers were retrieved. Thirty-one
papers (20 from the original review and 11 from the update)
describing 67 studies and involving 5,147 participants (sample
size=8,318) were included in the review [20,30–59]. A list of
excluded articles with their reasons for exclusion is provided in
Text S4.
Included studies. Of 67 total studies, six (9%) were reported
in languages other than English: Spanish (2), Turkish (1), Chinese
(1), Bosnian (1), and Russian (1). Thirty-two (48%) studies were
conducted in low- and middle-income countries. No studies were
randomized controlled trials; 55% of studies used a cross-sectional
study design, and 45% of studies used a case-control study design.
All but one study reported recruiting TB and non-TB patients
from the same underlying population [56]. One study involved
HIV-infected individuals, and no studies involved children.
Thirty-one (46%) studies involved smear-positive patients, 28
(42%) studies involved smear-negative patients, and eight (12%)
studies involved patients with unspecified smear status. Fifty-four
(81%) studies used ELISA, 12 (18%) studies used an
immunochromatographic assay, and one study used a kaolin
precipitation test. The majority of studies detected only IgG
antibody (44 studies) and used frozen serum (51 studies). The
median number of TB patients included in each study was 41
(interquartile range 33 to 54). Eighteen serological tests were
included; anda-TB (IgG, IgA, and IgM) was the test most
frequently evaluated (16/67 [24%]) (Table 1). The antigen
composition for five (28%) of the total 18 tests was considered
proprietary information. Of the tests with known antigens, all had
unique antigenic compositions except for anda-TB and Hexagon,
which both contained antigen A60.
One study directly compared a serological test to sputum
microscopy. No studies evaluated the incremental value of adding
a serological test after smear microscopy. However, as noted, 28
(42%) studies involved smear-negative patients. These studies were
considered a proxy for a diagnostic strategy using serological tests
in addition to microscopy. No studies reported on patient-
important outcomes or patient values and preferences concerning
these tests. Characteristics of included studies are described in
Table S2.
Methodological quality, all included studies. As assessed
with QUADAS, studies had very serious limitations. Of the total
67 studies only 19 (28%) were considered to include a
representative patient population (we scored this item as ‘‘yes’’
when ambulatory patients suspected of having active TB were
randomly or consecutively selected), and 34 (51%) studies reported
blinding of the serological test result. The majority (60%) of studies
reported industry involvement, mainly the donation of test kits
(Figure 2). We downgraded two points for limitations in the
GRADE Evidence Profile (Table 3).
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in Figure 3, studies displayed considerable heterogeneity, with
sensitivity values ranging from 0% to 100% and specificity values,
from 31% to 100%. We did not pool accuracy estimates because
of the heterogeneity among studies. Similarly, when restricted to
studies conducted in low- and middle-income countries, sensitivity
(16% to 91%) and specificity (31% to 100%) were highly variable
(data not shown).
Methodological quality, studies in smear-negative pa-
tients. As assessed with QUADAS, only 14 (50%) of the total 28
studies were considered to include a representative patient
population. A majority (75%) of studies reported blinding of the
serological test result (Figure 4). We downgraded one point for
limitations in the GRADE Evidence Profile (Table 4).
Test performance, studies in smear-negative patients. For
individual studies involving smear-negative patients, sensitivity values
ranged from 29% to 77%, and specificity values, from 77% to 100%
(Figure 5). We did not pool accuracy estimates because of the
considerable heterogeneity among studies. As noted above, studies
involving smear-negative patients were considered to provide indirect
evidence of a diagnostic strategy using microscopy plus serology.
Hence, as an add-on test, serological tests provided inconsistent
sensitivity and specificity.
Analysis by subgroups. According to our prespecified
analysis plan, there was a sufficient number of studies to
perform a meta-analysis for only one serological test, anda-TB
IgG, with results stratified by smear status (seven studies of smear-
positive and four studies of smear-negative patients). In studies of
Figure 1. Flow of studies in the review of commercial serological tests for the diagnosis of active tuberculosis.
doi:10.1371/journal.pmed.1001062.g001
Serological Tests for TB
PLoS Medicine | www.plosmedicine.org 5 August 2011 | Volume 8 | Issue 8 | e1001062smear-positive patients, one study was conducted in a low-income
country [43]. In studies of smear-negative patients, no studies were
conducted in a low- or middle-income country.
Methodological quality of studies evaluating anda-TB
IgG. In studies of smear-positive patients, no studies were
considered to have a representative patient population (participants
were known TB cases rather than suspected cases, were inpatients,
and/or were enrolled by convenience), and only two studies reported
blinding of the serological test result [43,52] (Figure S1). In studies of
smear-negative patients, no studies were considered to have a
representative patient population (participant selection was by
convenience or not reported), and only one study reported blinding
of the serological test result [52] (Figure S2).
Meta-analysis. In studies involving smear-positive patients,
anda-TB IgG yielded a pooled sensitivity of 76% (95% CI 63–87)
and a pooled specificity of 92% (95% CI 74–98). In studies
involving smear-negative patients, the pooled sensitivity of anda-
TB IgG decreased to 59% (95% CI 10–96); the 95% CI was very
wide, reflecting the imprecision of the sensitivity estimate. Pooled
specificity was 91% (95% CI 79–96) (Table 2). The HSROC
curves show the decreased performance of the test in smear-
negative patients compared with smear-positive patients (Figure 6).
Table 1. Commercial serological tests included in this systematic review for pulmonary TB.
Name of Test
(Number of Studies)
Name of Manufacturer
a,
City, Country Antigenic Composition
Antibodies
Detected
Laboratory
Technique
Detect-TB (2) Adaltis—Advanced Laboratory
Diagnostics Systems, Rome, Italy
Proprietary, a cocktail of three
M. tuberculosis recombinant proteins
and two synthetic peptides from
five different proteins
IgG ELISA
anda-TB ELISA
b (16) Anda Biologicals, Strasbourg, France A60 IgG, IgM, IgA,
IgG plus M
ELISA
Tuberculosis Specific
Antigen (1)
Chengdu Pharmaceutical,
Chengdu, China
Proprietary Unknown ELISA
Kaolin Agglutination Test (1) Hitech Laboratories, Bombay, India Tuberculophosphatide IgG Agglutination test
Hexagon TB (1) Human Gesellschaft fu ¨r Biochemica
und Diagnostica, Wiesbaden, Germany
A60 IgG, IgA, IgM ICT
Mycobacterium
tuberculosis IgG (1)
IBL, Hamburg, Germany 18 kDa, 36 kDa, and 40
kDa recombinant antigens
IgG, IgA, IgM ELISA
ICT TB (3) ICT Diagnostics, Sydney, Australia 38 kDa and four proprietary antigens;
all five antigens are recombinant
IgG ICT
ActiveTBDetect (1) InBios International, Seattle, US Mtb81, Mtb8, Mtb48, DPEP (MPT32),
38 kDa protein, and two additional
proprietary antigens
IgG ELISA
SEVA (1) Jamnalal Bajaj Tropical Disease Research
Centre, Mahatma Gandhi Institute of
Medical Sciences, Maharashtra, India
31 kDa, native glycoprotein antigen
from culture filtrate of MTB H37Rv
IgG ELISA
TB Enzyme Immunoassay (5) Kreatech, Amsterdam, The Netherlands Kp-90 antigenic compound: LAM,
10 kDa, 16 kDa, 21 kDa, 30 kDa,
34 kDa, 65 kDa, and 95 kDa
IgG, IgA ELISA
Determiner TB
Glycolipid Assay (6)
Kyowa Medex, Tokyo, Japan Contains trehalose 6,69-dimycolate,
trehalose monomycolate, diacyltrehalose,
phenolic glycolipid, 2,3,6,6-tetraacyl-
trehalose-2-sulfate, and 2,3,6-triacyl-trehalose
IgG ELISA
Assure TB (2) MedTek, Paranque City, Philippines;
and Genelabs Diagnostics, Singapore
Proprietary, two recombinant antigens IgG ICT
MycoDot (3) Mossman Associates, Milford,
Massachusetts, US
LAM IgG ICT
Pathozyme Myco
c (11) Omega Diagnostics, Alva, Scotland LAM, recombinant 38 kDa IgG, IgA, IgM ELISA
Pathozyme TB Complex (2) Omega Diagnostics, Alva, Scotland Recombinant 38 kDa IgG ELISA
Pathozyme TB Complex Plus
d (9) Omega Diagnostics, Alva, Scotland Recombinant 38 kDa and 16 kDa IgG ELISA
SDHO MTB (1) SDHO Laboratories, Saint-Sauveur
des Monts, Canada
Proprietary IgG ICT
Serocheck-MTB (1) Zephyr Biomedicals, Verna, India Recombinant 14 kDa, 38 kDa,
16 kDa, and 6 kDa
Unknown ICT
ICT, immunochromatographic test; LAM, lipoarabinomannan.
aSome manufacturers may no longer provide the serological tests listed above. It is also possible that the same test may be marketed under various names by different
companies.
banda-TB: IgG (13 studies), IgM (one study), IgA (two studies).
cPathozyme Myco: IgG (three studies), IgM (two studies), IgA (two studies), IgG plus IgM (one study), IgG plus IgA (one study), IgM plus IgA (one study), IgG plus IgM
plus IgA (one study).
dPathozyme TB Complex Plus as a single test (three studies) or in combination with Pathozyme Myco G (one study), Pathozyme Myco M (one study), Pathozyme Myco A
(one study), Pathozyme Myco G and A (one study), Pathozyme Myco M and A (one study), Pathozyme Myco G, M, and A (one study).
doi:10.1371/journal.pmed.1001062.t001
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accuracy. Compared with ELISA (pooled sensitivity 60% [95%
CI 6–65]; pooled specificity 98% [95% CI 96–99]), immunochro-
matographic assays yielded lower pooled sensitivity (53%, 95% CI
42–64) and comparable pooled specificity (98%, 95% CI 94–99)
(Table 2; Figure 7). The probability that the pooled sensitivity of
ELISA tests exceeds that of immunochromatographic assays was
estimated at 0.88.
TB in HIV-infected patients. The only study identified
involving HIV-infected patients compared the performance of the
Figure 2. Methodological quality graph, all studies, pulmonary TB. Review authors’ judgments about each methodological quality item.
doi:10.1371/journal.pmed.1001062.g002
Table 2. Bivariate meta-analyses: pooled sensitivity and specificity estimates by subgroup.
Subgroup Number of Studies Number of Participants (Sample Size) Sensitivity Specificity
Pulmonary TB
anda-TB IgG, smear-positive 7 870 (870) 76 (63–87) 92 (74–98)
anda-TB IgG, smear-negative 4 700 (700) 59 (10–96) 91 (79–96)
ELISA 54 3,696 (6,434) 60 (6–65) 98 (96–99)
Immunochromatographic Test
a 12 1,231 (1,512) 53 (42–64) 98 (94–99)
Extrapulmonary TB
Lymph node TB 6 640 (922) 64 (28–92) 90 (76–97)
Pleural TB 5 322 (572) 46 (29–63) 87 (51–99)
anda-TB IgG 10 1,055 (1,637) 81 (49–97) 85 (77–92)
Sensitivity and specificity estimates given as posterior means (percent) with 95% credible intervals in parentheses.
aSerological tests included: ICT TB (three studies), Assure TB (two studies), MycoDot (three studies), SDHO (two studies), Hexagon (one study), Serocheck-MTB (one
study).
doi:10.1371/journal.pmed.1001062.t002
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microscopy in 55 individuals suspected of having pulmonary TB
residing in the Central African Republic [44]. TB was confirmed
by culture. Compared with smear microscopy (sensitivity 68%
[95% CI 49–83]), SDHO yielded a sensitivity of only 16% (95%
CI 5–34). Specificity of SDHO was 90% (95% CI 74–98), lower
than the specificity of smear microscopy (100% [95% CI 89–100]).
Extrapulmonary TB
Results of the search. Twelve papers (nine from the original
review and three from the update) describing 25 studies and
involving 1,809 participants (sample size=3,776) were included in
the review (Figure 1) [45,48,60–69].
Included studies. Of 25 total studies, ten (40%) studies were
conducted in low- and middle-income countries. All papers were
written in English. Only one study involved HIV-infected
individuals. The vast majority (88%) of studies involved adults.
In two studies (reported from one paper), 13 of 35 extrapulmonary
TB cases occurred in children; however, data were not provided
separately for the children [67]. One study specified 13 y as the
minimum age for eligibility; however, the age range for the
enrolled participants was not reported [64]. Of 25 total studies,
serological tests were evaluated for diagnosis of the following forms
of extrapulmonary TB: lymph node, six studies; pleural, five
studies; multiple sites, five studies (see Table S3 for a list of sites
involved); genitourinary, two studies; disseminated, four studies;
and meningeal, one study. In two studies, the site of extra-
pulmonary involvement was not reported. Six distinct serological
tests were evaluated; 17 (68%) of the total 25 studies used anda-TB
(IgG, ten studies; IgM, five studies; IgA, one study; IgM plus IgA,
one study). ELISA was used in 21 (84%) studies, and
immunochromatographic assays, in four studies. The majority
(72%) of studies detected IgG antibodies. The condition of the
specimen was frozen in six (24%) studies and not reported in 19
studies. The median number of TB patients included in each study
was 35 (interquartile range 30 to 56). No studies reported on
patient-important outcomes or patient values and preferences
concerning these tests. Characteristics of included studies are
described in Table S3.
Methodological quality, all included studies. Of the 25
total studies, only one (4%) study was considered to include a
representative patient population, and only four (16%) studies
reported blinding of the serological test result (Figure 8).
Test performance, all studies. As seen from the forest plots
in Figure 9, studies displayed considerable heterogeneity, with
sensitivity values ranging from 0% to 100%, and specificity values,
from 59% to 100%. We did not pool accuracy estimates because
of the heterogeneity among studies.
Analysis by subgroups. There was a sufficient number of
studies to perform a meta-analysis for only one serological test,
Table 3. GRADE evidence profile: should commercial serological tests be used as a replacement test for conventional tests such as
smear microscopy in patients of any age suspected of having pulmonary tuberculosis?
Outcome
Number of
Studies
(Participants)
Study
Design Limitations Indirectness Inconsistency Imprecision
Publication
Bias
Final
Quality
Effect per
1,000
a Importance
b
True
Positives
67 (5,147) Cross-
sectional
and case-
control
Very serious
c
(22)
No serious
indirectness
d
Very serious
e
(22)
Serious
f Likely
g Very low
›qqq
Prevalence
10%: 64;
prevalence
30%: 192
Critical
True
Negatives
67 (5,147) Cross-
sectional
and case-
control
Very serious
c
(22)
No serious
indirectness
d
Very serious
e
(22)
Serious
f Likely
g Very low
›qqq
Prevalence
10%: 819;
prevalence
30%: 637
Critical
False
Positives
67 (5,147) Cross-
sectional
and case-
control
Very serious
c
(22)
No serious
indirectness
d
Very serious
e
(22)
Serious
f Likely
g Very low
›qqq
Prevalence
10%: 81;
prevalence
30%: 63
Critical
False
Negatives
67 (5,147) Cross-
sectional
and case-
control
Very serious
c
(22)
No serious
indirectness
d
Very serious
e
(22)
Serious
f Likely
g Very low
›qqq
Prevalence
10%: 36;
prevalence
30%: 108
Critical
Based on sample size=8,318, sensitivity median=64%, specificity median=91%. The quality of evidence was rated as high (no points subtracted), moderate (one point
subtracted), low (two points subtracted), or very low (.2 points subtracted) based on five factors: study limitations, indirectness of evidence, inconsistency in results
across studies, imprecision in summary estimates, and likelihood of publication bias. For each outcome, the quality of evidence started at high when there were
randomized controlled trials or high-quality observational studies (cross-sectional or cohort studies enrolling patients with diagnostic uncertainty) and at moderate
when these types of studies were absent. No points were subtracted when there were negligible issues identified; one point was subtracted when there was a serious
issue identified; two points were subtracted when there was a very serious issue identified in any of the criteria used to judge the quality of evidence. Points subtracted
are in parentheses. Publication bias was rated as ‘‘not likely,’’ ‘‘likely,’’ or ‘‘very likely’’ [23].
aWhat do these results mean given 10% or 30% disease prevalence among individuals being screened for TB?
bOutcomes were ranked by their relative importance as critical, important, or of limited importance. Ranking helped to focus attention on those outcomes that were
considered most important.
cThe majority of studies lacked a representative patient population and were not blinded.
dAlthough diagnostic accuracy is considered a surrogate for patient-important outcomes, we did not downgrade.
eThere was considerable heterogeneity in study results.
fWe did not pool accuracy estimates. The 95% CIs were wide for many individual studies. We did not downgrade as there were a large number of studies and we had
already taken off two points for inconsistency.
gData included in the review did not allow for formal assessment of publication bias using methods such as funnel plots or regression tests. Therefore, publication bias
cannot be ruled out. It is prudent to assume some degree of publication bias as studies showing poor performance of serological tests were probably less likely to be
published. No points were deducted.
doi:10.1371/journal.pmed.1001062.t003
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PLoS Medicine | www.plosmedicine.org 8 August 2011 | Volume 8 | Issue 8 | e1001062Figure 3. Forest plots of sensitivity and specificity, all studies, pulmonary TB. Specificity data for Mizusawa et al. [49] were not reported.
FN, false negative; FP, false positive; TN, true negative; TP, true positive. 95% CIs are included in brackets. On the right, the sensitivity and specificity
estimates for individual studies are indicated by blue squares and the 95% CIs are indicated by black horizontal lines.
doi:10.1371/journal.pmed.1001062.g003
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methodological quality item.
doi:10.1371/journal.pmed.1001062.g004
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income countries, one study was conducted in India [61], and one
study, in Turkey [66].
Methodological quality of studies evaluating anda-TB
IgG. As assessed with QUADAS, studies had very serious
limitations. No studies were considered to have a representative
population (no studies reported selecting participants in a consecutive
or random manner), and no studies reported interpreting the results
of the serological test result without knowledge of the results of the
reference standard.
Meta-analysis. We determined pooled sensitivity and speci-
ficity estimates for studies evaluating any serological test for the
diagnosis of lymph node or pleural TB and for studies using anda-
TB IgG (all extrapulmonary sites). For lymph node TB, pooled
sensitivity was 64% (95% CI 28–92) and pooled specificity was
90% (95% CI 76–97). For pleural TB, pooled sensitivity was 46%
(95% CI 29–63) and pooled specificity was 87% (95% CI 51–99).
For anda-TB IgG, pooled sensitivity was 81% (95% CI 49–97) and
pooled specificity was 85% (95% CI 77–92) (Table 2). For all three
meta-analyses, the 95% CIs for sensitivity were wide, reflecting the
imprecision of the estimates.
TB in HIV-infected patients. The only study identified
involving HIV-infected patients evaluated the performance of the
MycoDot test (Mossman Associates) in a cross-sectional study of
patients suspected of having TB in Thailand [68]. In all, 142 HIV-
infected (mean CD4 cell count=188 cells/mm
3 [range 7 to 632])
and 144 HIV-uninfected patients with newly diagnosed TB
participated in the study, of whom 50 patients (40 HIV-infected
and ten HIV-uninfected patients)had a diagnosis oflymph node TB
established by culture or histopathological examination. Compared
with the sensitivity of MycoDot in HIV-uninfected TB patients
(80%, 95% CI 44–98), the sensitivity of the test in HIV-infected TB
patients was considerably lower (33%, 95% CI 19–39). The
specificity in both groups was 97% (95% CI 93–99) (Table S3).
GRADE Evidence Profiles
Forthe pulmonaryTB studies,thequalityof the body ofevidence
supporting TB serology’s estimates of sensitivity and specificity was
graded as ‘‘very low’’ (Tables 3 and 4). Thus, regardless of the width
of the 95% CIs (which reflects the size of studies and the standard
deviation of their measured results), we have very low confidence in
the estimates obtained from pooling studies in the meta-analysis
[23]. For the extrapulmonary TB studies, the final quality grades
were also very low (data not shown).
Discussion
This updated systematic review assessing the diagnostic
accuracy of commercial serological tests for pulmonary and
extrapulmonary TB summarizes the current literature and
includes 14 new papers (approximately 30% of the included
papers) identified since our previous reviews [12,13]. Unlike the
earlier reviews, in the update, we performed a meta-analysis using
a bivariate random effects model to account for the variability in
Table 4. GRADE evidence profile: should commercial serological tests be used as an ‘‘add on’’ test to smear microscopy in patients
of any age suspected of having pulmonary TB?
Outcome
Number of
Studies
(Participants)
Study
Design Limitations Indirectness Inconsistency Imprecision
Publication
Bias
Final
Quality
Effect per
1,000
a Importance
b
True
Positives
28 (1,961) Mainly
cross-
sectional
Serious
c
(21)
Serious
d
(21)
Very serious
e
(22)
Serious
f Likely
g Very Low
›qqq
Prevalence
10%: 61
Critical
True
Negatives
28 (1,961) Mainly
cross-
sectional
Serious
c
(21)
Serious
d
(21)
Very serious
e
(22)
Serious
f Likely
g Very Low
›qqq
Prevalence
10%: 828
Critical
False
Positives
28 (1,961) Mainly
cross-
sectional
Serious
c
(21)
Serious
d
(21)
Very serious
e
(22)
Serious
f Likely
g Very Low
›qqq
Prevalence
10%: 72
Critical
False
Negatives
28 (1,961) Mainly
cross-
sectional
Serious
c
(21)
Serious
d
(21)
Very serious
e
(22)
Serious
f Likely
g Very Low
›qqq
Prevalence
10%: 39
Critical
This table includes studies conducted in smear-negative patients as a proxy for a diagnostic strategy using serological tests in addition to smear microscopy. Based on
sample size=3,433, sensitivity median=61% and specificity median=92%. The quality of evidence was rated as high (no points subtracted), moderate (one point
subtracted), low (two points subtracted), or very low (.2 points subtracted) based on five factors: study limitations, indirectness of evidence, inconsistency in results
across studies, imprecision in summary estimates, and likelihood of publication bias. For each outcome, the quality of evidence started at high when there were
randomized controlled trials or high-quality observational studies (cross-sectional or cohort studies enrolling patients with diagnostic uncertainty) and at moderate
when these types of studies were absent. No points were subtracted when there were negligible issues identified; one point was subtracted when there was a serious
issue identified; two points were subtracted when there was a very serious issue identified in any of the criteria used to judge the quality of evidence. Points subtracted
are in parentheses. Publication bias was rated as ‘‘not likely,’’ ‘‘likely,’’ or ‘‘very likely’’ [23].
aWhat do these results mean given 10% disease prevalence among individuals being screened for TB?
bOutcomes were ranked by their relative importance as critical, important, or of limited importance. Ranking helped to focus attention on those outcomes that were
considered most important.
cOnly 14/28 (50%) studies were considered to include a representative patient population; 75% of studies reported blinding of the serological test result.
dWe downgraded for indirectness because these studies were used as a proxy for a diagnostic strategy using serological tests in addition to smear microscopy.
eThere was considerable heterogeneity in study results.
fWe did not pool accuracy estimates. The 95% CIs were wide for many individual studies. We did not downgrade as there were a large number of studies and we had
already taken off two points for inconsistency.
gData included in the review did not allow for formal assessment of publication bias using methods such as funnel plots or regression tests. Therefore, publication bias
cannot be ruled out. It is prudent to assume some degree of publication bias as studies showing poor performance of serological tests were probably less likely to be
published. No points were deducted.
doi:10.1371/journal.pmed.1001062.t004
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similar to those of the previous review: studies of current
serological tests show that these tests provide inaccurate and
imprecise estimates of sensitivity and specificity.
In the earlier systematic reviews, we recommended the use of
guidelines such as STARD (Standards for the Reporting of
Diagnostic Accuracy Studies) [70] and QUADAS [21] to improve
methodological study quality. In the current review, within-study
quality continues to be a concern. For example, in the pulmonary
TB group there were 16 new studies. Six of these studies (three
papers) were published subsequent to the previous reviews
[20,37,49]. Four of the six studies selected participants by
convenience or did not report the manner of selection (selection
bias), and no studies reported that the serological test result was
interpreted without knowledge of the reference standard. Selection
bias and absence of blinding are features of study design that have
been associated with exaggerated accuracy estimates [71,72].
A substantial contribution of the current review is the use of the
GRADE approach. This framework enabled us to synthesize data
on the quality of the body of evidence in a way that was not possible
for the previous systematic reviews [12,13] because GRADE was
not well developed for diagnostic studies at that time. The very low
qualityofevidenceforthestudiesevaluatinganda-TBIgGinsmear-
negative patients decreases our confidence in the pooled sensitivity
and specificity estimates. In this subgroup, applying the GRADE
approach, quality was compromised by three factors: (1) risk of bias:
no studies recruited participants in a random or consecutive
manner, and only one study reported blinded interpretation of the
serological test result; (2) indirectness: no studies were conducted in
low- or middle-income countries, limiting generalizability to these
settings; and (3) imprecision. If the pooled estimates of test accuracy
had been derived from high-quality studies, then the serological test
might have been shown to have some clinical utility for contributing
to diagnostic algorithms for smear-negative TB, especially since the
tests are relatively inexpensive, rapid, and easy to perform.
However, the very low quality of the evidence implies that the
serological test cannot be recommended.
Strengths and Limitations
Strengthsofourreviewinclude the useofa standard protocoland
comprehensive search strategy, two independent reviewers at all
stages of the review process, the assessment of methodological
quality of individual studies with the QUADAS tool, and the use of
the GRADE approach. Heterogeneity is to be expected in results of
diagnostic test accuracy studies [73]. Therefore, we prespecified
subgroups to limit heterogeneity and, as noted above, used a
bivariate random effects model. Our review also had limitations,
notably, the majority of studies were not considered to include
patients with a representative spectrum of disease severity. Differing
criteria for patient selection and greater duration and severity of
illness of the study populations may have introduced variability in
findings among studies. In addition, the majority of studies were not
performed in a blinded manner, or blinding was not explicitly
stated. Also, the meta-analysis was limited by the small number of
Figure 5. Forest plots of sensitivity and specificity, pulmonary TB, studies of smear-negative patients. FN, false negative; FP, false
positive; TN, true negative; TP, true positive. 95% CIs are included in the brackets. On the right, the sensitivity and specificity estimates for individual
studies are indicated by blue squares, and the 95% CIs are indicated by black horizontal lines.
doi:10.1371/journal.pmed.1001062.g005
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test with enough studies for meta-analysis. Clearly, having more
studies would have allowed us to examine observed, study-level
covariates that could be sources of heterogeneity. An additional
limitation was that, in some cases, we assumed that multiple results
carried out on the same sample were independent. By doing so, our
meta-analysis model may have underestimated heterogeneity and
overestimated precision of the pooled sensitivity and specificity
estimates by including a larger number of participants. Subgroup
analyses in a meta-analysis, like subgroup analyses in a clinical trial,
are vulnerable to bias; therefore, the findings of this meta-analysis
should be interpreted with caution [74]. Although we tried to
address language bias by performing the updated literature search
in all languages, the original literature search was limited to studies
published in English, and language bias remains a possibility.
Finally, our review did not allow for formal assessment of
publication bias using methods such as funnel plots or regression
tests because such techniques have not been adequately evaluated
for diagnostic data [75]. Therefore,publication bias cannot be ruled
out. However, it is prudent to assume some degree of publication
bias, as studies showing poor performance of serological tests may
have been less likely to be published, especially because several
studies were industry supported.
This systematic review focused on test accuracy (i.e.,
sensitivity and specificity). Although, we looked for information
on patient-important outcomes (meaning a serological test used
Figure 6. Summary HSROC plots of sensitivity and specificity for anda-TB IgG in smear-positive and smear-negative pulmonary TB
patients. Smear-positive (line A; open circles) and smear-negative (line B; gray circles) pulmonary TB patients. The width of the circles is proportional
to the number of patients in each study. The red squares are the summary values for sensitivity and specificity.
doi:10.1371/journal.pmed.1001062.g006
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in patient care and/or outcomes), we did not find this
information in the literature reviewed. We did not identify
studies with the specific aim of detecting the value of serology
over and above conventional tests such as smears. However, the
WHO Special Programme for Research and Training in
Tropical Diseases report on rapid serological tests for TB
mentioned above did evaluate the added value of smear plus
serology and reported a gain equivalent to the detection of 57%
of the smear-negative, culture-positive TB cases. There was,
however, a corresponding unacceptable decrease in specificity
to 58% [15].
In conclusion, published data on commercial serological
tests produce inconsistent and imprecise estimates of sensitivity
and specificity, and the quality of the body of evidence on these
tests remains disappointing. This systematic review included
evaluations of only commercially available antibody-based
detection tests. Considerable research is underway on new
approaches to the serological diagnosis of TB. These
approaches include the use of newly identified selected purified
recombinant antigens and antigen combinations [14]. Recent
studies from a number of laboratories have reported several
new potential candidate antigens that may be expected to lead
to improved antibody detection tests for TB in the future.
These conclusions should be reconsidered if, in the future,
methodologically adequate research evaluating serological tests
becomes available.
T h ef i n d i n g sf r o mt h i ss y s t e m a t i cr e v i e ww e r eu s e da st h e
input for a cost-effectiveness study of serological testing for
active TB in India [76]. In comparison with sputum
Figure 7. Summary HSROC plots of sensitivity and specificity by assay technique. ELISA (line A; open circles) and immunochromatographic
test (line B; gray circles). The width of the circles is proportional to the number of patients in each study. The red squares are the summary values for
sensitivity and specificity.
doi:10.1371/journal.pmed.1001062.g007
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PLoS Medicine | www.plosmedicine.org 14 August 2011 | Volume 8 | Issue 8 | e1001062Figure 8. Methodological quality summary, all studies, extrapulmonary TB. Review authors’ judgments about each methodological quality item.
doi:10.1371/journal.pmed.1001062.g008
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adjusted life years averted and more false-positive diagnoses
and secondary infections, while increasing costs to the Indian
TB control sector approximately 4-fold. This cost-effectiveness
study and the findings from our updated systematic review were
considered by a WHO Expert Group on Serodiagnostics, and
in July 2011, the WHO published a policy statement on
commercial serodiagnostic tests for diagnosis of TB. The policy
states that ‘‘Commercial serological tests provide inconsistent and
imprecise estimates of sensitivity and specificity. There is no
evidence that existing commercial serological assays improve
patient-important outcomes, and high proportions of false-positive
and false-negative results adversely impact patient safety. Overall
data quality was graded as very low, with harms/risks far
outweighing any potential benefits (strong recommendation). It is
therefore recommended that these tests should not be used in
individuals suspected of active pulmonary or extra-pulmonary TB,
irrespective of their HIV status.’’ The WHO policy strongly
encourages targeted further research to identify new/alternative
point-of-care tests for TB diagnosis and/or serological tests with
improved accuracy [77].
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Background Every year nearly 10 million people develop
tuberculosis—a contagious bacterial infection—and about
two million people die from the disease. Mycobacterium
tuberculosis, the bacterium that causes tuberculosis, is spread
in airborne droplets when people with the disease cough or
sneeze. It usually infects the lungs (pulmonary tuberculosis)
but can also infect the lymph nodes, bones, and other tissues
(extrapulmonary tuberculosis). The characteristic symptoms
of tuberculosis are a persistent cough, weight loss, and night
sweats. Diagnostic tests for the disease include microscopic
examination of sputum (mucus brought up from the lungs
by coughing) for M. tuberculosis bacilli, chest radiography,
mycobacterial culture (in which bacteriologists try to grow
M. tuberculosis from sputum or tissue samples), and nucleic
acid amplification tests (which detect the bacterium’s
genome in patient samples). Tuberculosis can usually be
cured by taking several powerful drugs daily or several times
a week for at least six months.
Why Was This Study Done? Although efforts to control
tuberculosis have advanced over the past decade, missed
tuberculosis diagnoses and mismanaged tuberculosis
continue to fuel the global epidemic. A missed diagnosis
may lead to more severe illness and death, especially for
peopleinfected withboth tuberculosisandHIV. Also,a missed
diagnosis means that an untreated individual with pulmonary
tuberculosis may remain infectious for longer, continuing to
spread tuberculosis within the community Missed diagnoses
are a particular problem in resource-limited countries where
sputum microscopy and chest radiography often perform
poorly and other diagnostic tests are too expensive and
complex for routine use. Serological tests, which detect
antibodies against M. tuberculosis in the blood (antibodies are
proteins made by the immune system in response to
infections), might provide a way to diagnose tuberculosis in
resource-limited countries. Indeed, many serological tests for
tuberculosis diagnosis are on sale in developing countries.
However, because of doubts about the accuracy of these
commercial tests, they are not recommended for use in
routine practice. In this systematic review and meta-analysis,
the researchers assess the diagnostic accuracy of commercial
serological tests for pulmonary and extrapulmonary
tuberculosis. A systematic review uses predefined criteria to
identify all the research on a given topic; meta-analysis is a
statistical method that combines the results of several studies.
What Did the Researchers Do and Find? The researchers
searched the literature for studies that evaluated serological
tests for active tuberculosis published between 1990 and
2010. They used data from these studies to calculate each
test’s sensitivity (the proportion of patients with a positive
serological test among patients with tuberculosis confirmed
by a reference method; a high sensitivity indicates that the
test detects most patients with tuberculosis) and specificity
(the proportion of patients with a negative serological result
among people without tuberculosis; a high specificity means
the test gives few false-positive diagnoses). They also
assessed the methodological quality of each study and
rated the overall quality of the evidence. The researchers
found 67 studies (half from low/middle-income countries)
that evaluated serological tests for the diagnosis of
pulmonary tuberculosis. The sensitivity of these tests varied
between studies, ranging from 0% to 100%; their specificities
ranged from 31% to 100%. For the anda-TB IgG test—the
only test with sufficient studies for a meta-analysis—the
pooled sensitivity from the relevant studies was 76% in
smear-positive patients and 59% in smear-negative patients.
The pooled specificities were 92% and 91%, respectively. The
researchers found 25 studies (40% from low/middle-income
countries) that evaluated serological tests for the diagnosis
of extrapulmonary tuberculosis. Again, sensitivities and
specificities for each test varied greatly between studies,
ranging from 0% to 100% and 59% to 100%, respectively.
Overall, for both pulmonary and extrapulmonary
tuberculosis, the quality of evidence from the studies of
the serological tests was graded very low.
What Do These Findings Mean? This systematic review,
which updates an analysis published in 2007, indicates that
commercial serological tests do not provide an accurate
diagnosis of tuberculosis. This finding confirms previous
systematic reviews of the evidence, despite a recent
expansion in the relevant literature. Moreover, the
researchers’ analysis indicates that the overall quality of the
body of evidence on these tests remains poor. Many of the
identified studies used unsatisfactory patient selection
methods, for example. Clearly, there is a need for
continued and improved research on existing serological
tests and for research into new approaches to the serological
diagnosis of tuberculosis. For now, though, based on these
findings, cost-effectiveness data, and expert opinion, the
World Health Organization has issued a recommendation
against the use of currently available serological tests for the
diagnosis of tuberculosis, while stressing the importance of
continued research on these and other tests that could
provide quick and accurate diagnosis of TB.
Additional Information Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001062.
N The World Health Organization provides information on all
aspects of tuberculosis, including information on tubercu-
losis diagnostics on the Stop TB Partnership (some
information is in several languages); the Strategic and
Technical Advisory Group for Tuberculosis recommenda-
tions on tuberculosis diagnosis are available
N The Web site Evidence-Based Tuberculosis Diagnosis (from
Stop TB Partnership’s New Diagnostics Working Group)
provides access to several resources on TB diagnostics,
including systematic reviews, guidelines, and training
materials
N The US Centers for Disease Control and Prevention has
information about tuberculosis, including information on
the diagnosis of tuberculosis disease
N The US National Institute of Allergy and Infectious Diseases
also has detailed information on all aspects of tuberculosis
N MedlinePlus has links to further information about
tuberculosis (in English and Spanish)
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